ArticleAdvances in radiation oncology2026
Outcomes Associated with Radiation Therapy for Localized Resectable Malignant Peripheral Nerve Sheath Tumors.
Article in Advances in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Malignant peripheral nerve sheath tumor (MPNST) is a rare, aggressive soft tissue sarcoma with highest incidence in patients with neurofibromatosis type 1 (NF1). Data on outcomes and second malignancies following radiation therapy (RT) are limited, particularly in patients with NF1. This study evaluated overall survival (OS), progression-free survival (PFS), local failure, and secondary malignancies in patients with localized resectable MPNST. Methods and Materials: Patients diagnosed with localized resectable MPNST between 2010 and 2024 were retrospectively identified. Survival was estimated using the Kaplan-Meier method, multivariable analysis was conducted using Cox proportional hazards modeling, and cumulative incidence was estimated using Fine and Gray model. Results: Sixty-eight patients met inclusion criteria; median age was 34 years, and 75% had NF1. Median follow-up was 43.5 months. RT was delivered in 61.8% of patients, primarily preoperatively (71.1%). RT was associated with improved 3-year OS (87.2% vs 51.5%, Conclusions: RT was independently associated with improved PFS and OS in patients with localized resected MPNST. These hypothesis-generating findings need validation in a larger cohort. The risk of RT-associated secondary malignancy was low, occurring beyond the median disease progression timeframe.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.